01 — At a Glance
The Chemical Rollercoaster That Makes Six Flags Look Boring
- 52-Week High / Low₹700 / ₹409
- Q3 FY26 Revenue₹1,044 Cr
- Q3 FY26 PAT₹-20 Cr
- Q3 Operating Margin9%
- Annualised EPS (Q3×4)₹-10.88
- FY25 Full-Year PAT₹-65 Cr
- Debt / Equity0.11x
- ROCE-0.34%
- ROE-1.13%
- Promoter Holding46.3%
The Quarterly Reality Check: Q3 FY26 delivered ₹1,044 crore revenue (+1.46% QoQ) but swung to a ₹-20 crore PAT loss (-77.6% QoQ). This is not a typo. This is a company where operating margins sit at a nice 9%, but somehow by the time you reach the bottom line, the money has vanished like a dahi handi at a Govardhan Puja celebration. FY25 full-year loss: ₹-65 crore. Stock is down 8.61% in one year. Welcome to caustic soda reality.
02 — Introduction
The Company That Sells Chemicals But Somehow Loses Money
Gujarat Alkalies & Chemicals Limited — GACL — is India’s third-largest caustic soda manufacturer by installed capacity. Founded in 1973 as a Government of Gujarat enterprise, it’s built a portfolio of 36 products, including caustic soda, chloromethanes, phosphoric acid, and hydrogen peroxide. Sounds profitable on paper. On paper.
The problem? GACL exists in one of the most cyclical, commodity-oriented, import-bruised, electricity-rate-sensitive, and structurally challenged industries in India. Caustic soda prices spike. Chlorine dumps. ECU realizations collapse. Then the government decides to build a new mega-capacity plant somewhere, and GACL’s margins vanish like chai at a construction site. Rinse, repeat, lose money.
Yet the company has ₹207 MW of wind farms, ₹36 MW of solar plants, ongoing ₹1,030 crore capex for boilers and phosphoric acid plants, and 46.3% ownership by Government of Gujarat entities. It’s state-backed, renewable-energy-forward, and structurally underprofitable. It’s like a Netflix series nobody asked for but keeps getting renewed anyway.
Q3 FY26 results were approved on February 6, 2026. The board also approved capex of ₹560 crore for a phosphoric acid plant, ₹389 crore for new boilers, and ₹80 crore for KOH expansion. And one director resigned. The drama never stops.
The Board Meeting Verdict (Feb 6, 2026): Approved Q3 results. Approved ₹1,030 crore capex. Approved ₹250 crore credit facility. Director S J Haider resigned effective Dec 31, 2025. Translation: money keeps flowing in; money keeps flowing out; profits remain mythical.
03 — Business Model: 36 Products. One Problem. Margins.
Making Chemicals That Everyone Needs But Nobody Wants To Pay For
GACL’s business model is straightforward. Buy raw materials (salt, water, electricity). Run them through electrochemical cells (energy-intensive, like running a server farm in a furnace). Make caustic soda, chlorine, hydrogen peroxide, and 33 other derivatives. Sell them to textile mills, pulp & paper plants, detergent makers, and aluminum processors across India and exports to 160+ countries.
The company holds 16% market share in caustic soda (down from glory days) and 23.5% in chloromethanes. It’s integrated — caustic soda plants sit next to chloromethane derivatives to reduce chlorine disposal costs. It has 207 MW of wind power and 36 MW of solar capacity to offset electricity bills. It even has a 60% stake in GNAL (GACL-NALCO Alkalies), a JV with Nalco that’s burning cash faster than a Bollywood hero’s credit card on a mall date.
But here’s the catch: In the chlor-alkali industry, when caustic prices spike, chlorine dumps. When chlorine tanks because of oversupply, caustic has to be sold at lower ECU realizations. When both are weak, GACL loses money on operations and relies on “other income” (interest, surplus power sales) to survive. FY25 PAT was negative ₹65 crore. FY24 was negative ₹237 crore. The company is not losing money; it’s losing money consistently.
Caustic Soda44%Revenue Mix FY24
Chloromethanes10%Revenue Mix FY24
Exported Revenue20%FY24 vs 13% FY22
Installed Capacity↑ 82%Utilization FY24
Capacity Utilization Reality: GACL had 110% capacity utilization in FY22 (basically running on fumes). FY24? 82%. FY25 data pending, but the trend is clear. More capacity. Less demand. Stronger headwinds. The company expanded aggressively right when the industry decided to soften.
💬 Here’s a question: If you’re losing money at 82% capacity utilization, how profitable are you going to be at 90%+? Should the board have approved ₹1,030 crore more capex?
04 — Financials Overview: The Quarterly Bloodbath
Q3 FY26: Revenue Up. Profit Down. The Formula That Works Perfectly Backwards
Result Type: Quarterly Results | Q3 FY26 EPS: ₹-2.72 | Annualised EPS (Q3×4): ₹-10.88 | FY25 Full-Year EPS: ₹-8.87
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,044 | 1,029 | 1,083 | +1.5% | -3.6% |
| Operating Profit | 96 | 78 | 74 | +23.1% | +29.7% |
| OPM % | 9% | 8% | 7% | +100 bps | +200 bps |
| PAT | -20 | -11 | 16 | +81.8% | -225% |
| EPS (₹) | -2.72 | -1.53 | 2.23 | +77.8% | -221.9% |
The Paradox Nobody Talks About: Operating profit is up 23% YoY, margins improved from 8% to 9%, but PAT swung from -₹11 Cr to -₹20 Cr. Why? Depreciation, interest, and taxes happened. GACL’s massive capex program means depreciation is brutal (~₹100 Cr quarterly). Interest is climbing (₹18 Cr in Q3, up from ₹10 Cr three years ago). Even with improving operations, the company can’t reach profitability because of its capital structure. This is the story of state-backed capex mismanagement.
05 — Valuation: Fair Value Range
How Do You Value a Company Losing Money?
Method 1: Price-to-Book (Discounted)
Book Value: ₹759/share (Sep 2025 BS shows ₹5,497 Cr reserves + ₹73 Cr equity = ₹5,570 Cr net worth ÷ 73.4 Cr shares). Current P/B: 0.64x. Industry median P/B for cyclical chemicals: 0.7x–1.0x. Given losses, a 0.6x–0.85x range is justified.
Range: ₹455 – ₹645
Method 2: EV/EBITDA (Forward-Adjusted)
TTM EBITDA (from P&L): ₹366 Cr. Current EV: ₹3,843 Cr. Current EV/EBITDA: 10.5x. Recovery scenario assumes EBITDA improves to ₹550 Cr (achievable at 90%+ capacity with modest price recovery). Fair EV/EBITDA: 7x–9x.
At 90% capacity & improved ECU: EBITDA ~₹550 Cr → Fair EV ₹3,850–4,950 Cr (net debt ₹429 Cr)
Range: ₹465 – ₹605
Method 3: Sum-of-Parts (JV Scenario)
GACL standalone is burning cash. But GNAL (60% JV with Nalco) is a separate beast. Full consolidation muddles the picture. Standalone GACL: ~₹350 Cr EBITDA potential (at 85% util). GNAL: ~₹200 Cr EBITDA potential (ramping up). Consolidation drag: ₹30 Cr. Total fair value spread.
→ GACL standalone (8x EBITDA): ~₹2,800 Cr
→ GNAL stake (60% of 7x): ~₹840 Cr
→ Net debt adj: -₹429 Cr
→ Per share fair value: ₹470–580
Range: ₹470 – ₹600
Fair Min: ₹450
CMP: ₹486 (Mid-Range Fair Value)
Fair Max: ₹630
⚠️ EduInvesting Fair Value Range: ₹450 – ₹630. CMP ₹486 sits within the fair-value range. This is a broken company trading at a discounted valuation for broken-company reasons. Fair value assumes recovery; current price assumes skepticism. This fair value range is for educational purposes only and is not investment advice.
06 — What’s Cooking: Capex, Closures, And Chaos
The Drama That Keeps This Stock From Sleeping
